Anlon Healthcare Limited has announced the completion of two significant acquisitions: Apiqo Organics Pvt. Ltd. and Bizotic Lifescience Pvt. Ltd., which have now become subsidiaries of the company. The acquisition of Apiqo Organics was completed for ₹5.40 crore, strengthening backward integration for critical pharmaceutical intermediates and industrial & fine chemicals. This acquisition provides a ready, established manufacturing platform with faster scalability and improves cost competitiveness. The acquisition of Bizotic Lifescience, for which a Share Purchase Agreement (SPA) has been executed with a consideration of ₹3.79 crore (cash), is expected to be completed within approximately three months. This move is strategic, providing a ready-to-operate manufacturing facility, accelerating capacity expansion, and strengthening regulatory readiness. These acquisitions are projected to significantly boost Anlon Healthcare's manufacturing capacity. With an existing capacity of 400 MTPA, the Bizotic acquisition adds an estimated 300-400 MTPA, and the Apiqo acquisition contributes an incremental 700-800 MTPA. This brings the total projected installed capacity to 1,400-1,600 MTPA by FY26. The company's strategy is to support a revenue CAGR of approximately 30% over the next three years. The company also reported its Q4 and FY26 results, with FY26 revenues reaching ₹171.97 crore and EBITDA margins at 27.74%. The company is also focusing on launching 7 new APIs in FY27 and diversifying into the Industrial & Fine Chemicals segment.
